APVO
Aptevo Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+1.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -10.3%
- EBIT
- -10.6%
- EPS
- +97.8%
- Free cash flow
- -2.8%
- Operating cash flow
- -2.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +96.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -8.2%
- EBIT
- -7.0%
- Net income
- -7.6%
- EPS
- +99.7%
- Free cash flow
- -7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026